Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03711604 · ClinicalTrials.gov registry record · Phase 1
Compassionate Use Study of Tenalisib (RP6530)
A Phase 1 study of Hematological Malignancies, sponsored by Rhizen Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 7
- Study locations
NCT03711604 is a Phase 1 study of Hematological Malignancies that has completed, run by Rhizen Pharmaceuticals. The registered enrollment target is 17 participants, below the 775-participant average among 16 other Hematological Malignancies trials with a reported enrollment target (98% lower). The trial reports 7 study locations across 5 states.
The verdict
NCT03711604, a Phase 1 study of Hematological Malignancies, has completed, sponsored by Rhizen Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 7
- Study locations
Study Summary
Tenalisib has been evaluated as an investigational new drug in number of early clinical studies in patients with relapsed/refractory hematological malignancies and demonstrated acceptable safety and promising efficacy in these patients. Since these advanced relapsed/refractory patients have limited therapeutic options, it is reasonable to continue Tenalisib in responding patients post completion of their participation in previous clinical studies.
Conditions Studied
Interventions
- DRUG Tenalisib
Study Locations (7)
Other
- Ltd. M.Zodelava Hematology Centre - Tbilisi
- Medivest - Institute of Hematology and Transfusiology - Tbilisi
- Silesian Healthy Blood Clinic Grosicki, Grosicka Sp.J. - Chorzów
California
- University of California, Hellen Diller Family Comprehensive Cancer Center - San Francisco
Colorado
- Division of Hematology, University of Colorado, - Denver
Ohio
- Cleveland Clinic Taussig Cancer Institute - Cleveland
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2018-11-28 |
| Est. Completion | 2023-03-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03711604
The ClinicalTrials.gov registry entry for NCT03711604 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 775-participant average among 16 other Hematological Malignancies trials with a reported enrollment target (98% lower). The listed sponsor is Rhizen Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematological Malignancies appearing as the primary indexed condition, and to 1 intervention - of which Tenalisib is the first listed.
NCT03711604 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Other, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT03711604 about?
NCT03711604 is a clinical study titled "Compassionate Use Study of Tenalisib (RP6530)". Tenalisib has been evaluated as an investigational new drug in number of early clinical studies in patients with relapsed/refractory hematological malignancies and demonstrated acceptable safety and promising efficacy in these patients. Since these advanced relapsed/refractory patients have limited ...
What is the current status of trial NCT03711604?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2018-11-28. Estimated completion is 2023-03-25.
What conditions does trial NCT03711604 study?
This clinical trial studies the following conditions: Hematological Malignancies.
What interventions are being tested in trial NCT03711604?
The interventions under investigation include: Tenalisib (DRUG).
Who is sponsoring clinical trial NCT03711604?
This trial is sponsored by Rhizen Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03711604 being conducted?
This trial has 7 study locations across California, Colorado, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematological Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
RECRUITING · Phase 1
-
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
RECRUITING · Phase 1
-
Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Durvalumab and Tremelimumab for Pediatric Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Study of AZD9829 in CD123+ Hematological Malignancies
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.